Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Core Insights - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [17] - The company reported a net loss of $26.7 million for Q2 2025, an increase from $18.1 million in the same period last year [14] - The company ended the quarter with $260.4 million in cash and equivalents, expected to fund operations through the end of 2026 [5][14] Business Highlights - The Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled, with topline results expected in September 2025 [5][8] - A Phase 2 trial of RAP-219 in bipolar mania has been initiated, with topline results anticipated in the first half of 2027 [9] - Plans for a Phase 2a trial in diabetic peripheral neuropathic pain are being finalized, with an update expected in 2025 [10] Financial Results - Research and Development (R&D) expenses for Q2 2025 were $22.7 million, up from $15.7 million in the prior year [14] - General and Administrative (G&A) expenses increased to $6.8 million from $5.1 million year-over-year [14] - The company reported a net loss per share of $0.75 for Q2 2025, compared to $1.70 for the same period in 2024 [24] Clinical Development Updates - The Phase 2a trial of RAP-219 is designed to assess its effect on long episodes (LEs) in patients, with a primary endpoint of achieving a ≥30% reduction in LEs [6] - The trial population shows a concordance of 92% between long episodes and electrographic seizures, with patients experiencing an average of 51 long episodes per 28 days [6] - The company expects to analyze the proportion of patients achieving a ≥50% reduction in clinical seizures as a key secondary endpoint [6] Corporate Updates - Rapport hosted its inaugural Investor and Analyst Day on June 2, 2025, featuring presentations from key executives and discussions with leading epilepsy experts [11] - The company is committed to a disciplined approach in advancing its pipeline and delivering transformative treatments for patients [2]